Comprehensive evidence-based tools for cardiovascular care
This application was created for demonstration only. Do not use for educational or clinical purposes.
Using patient height and weight from above
Low Risk (<5%): Lifestyle modifications, reassess in 4-6 years
Borderline Risk (5-7.5%): Consider risk enhancers, shared decision-making
Intermediate Risk (7.5-20%): Statin therapy recommended, consider risk enhancers
High Risk (≥20%): High-intensity statin therapy, consider additional agents
First-line therapy: ACE inhibitor/ARB + Beta-blocker + Diuretic (if volume overload)
Second-line: Aldosterone antagonist, SGLT2 inhibitor
Advanced therapy: ARNI (sacubitril/valsartan), ivabradine, device therapy
Rate Control Target: Resting HR <110 bpm (lenient) or <80 bpm (strict)
Anticoagulation: CHA2DS2-VASc ≥2 (men) or ≥3 (women) - consider anticoagulation
Rhythm Control: Consider for symptomatic patients, younger patients, or first episode
VF/pVT: Immediate defibrillation at 200J (biphasic)
Asystole/PEA: CPR, epinephrine 1mg IV/IO every 3-5 minutes
30:2 compression to ventilation ratio, 100-120 compressions/min
Minimize interruptions, rotate compressors every 2 minutes
Epinephrine 1mg IV/IO every 3-5 minutes
Amiodarone 300mg IV for refractory VF/pVT
Hypovolemia, Hypoxia, Hydrogen ions, Hypo/hyperkalemia
Tension pneumothorax, Tamponade, Toxins, Thrombosis